Sangamo Therapeutics, a genomic medicine company, has shown significant potential despite recent challenges, including the termination of partnerships with Pfizer and Novartis. The company has a promising pipeline with a focus on neurology and genomic medicines, such as the ongoing STAAR study for Fabry Disease, which shows promise for accelerated approval. Sangamo's recent license agreements and potential upcoming submissions to regulatory bodies could act as catalysts for future growth. Investors should consider the company's high R&D investment and recent strategic partnerships, which may offset the risks associated with its past financial instability and partnership terminations.